Clinical efficacy of anti‐SARS‐CoV‐2 monoclonal antibodies in preventing hospitalisation and mortality among patients infected with Omicron variants: A systematic review and meta‐analysis

Until now, the treatment protocols for COVID‐19 have been revised multiple times. The use and approval of therapeutic monoclonal antibodies (mAbs) for COVID‐19 treatment represent exceptional achievements in modern science, technology and medicine. SARS‐CoV‐2 Omicron evasion of pre‐existing immunity represents a serious public health problem nowadays. This systematic review with meta‐analysis provided comprehensive and up‐to‐date evidence of the clinical efficacy of therapeutic anti‐SARS‐CoV‐2 mAbs against Omicron subvariants in COVID‐19 patients and included 10 articles. The prevalence of hospitalisation among Omicron‐positive patients treated with anti‐SARS‐CoV‐2 mAbs was 2.8% (89/3169) while it controls (Omicron‐positive patients treated with other therapies) 11% (154/1371). There was a statistically significantly different number of hospitalisations between the two studied groups in favour of the anti‐SARS‐CoV‐2 mAbs treated group. (OR = 0.56, 95% CI OR = 0.41–0.77, p